Skip to main content
Fig. 2: | Journal of Hematology & Oncology

Fig. 2:

From: Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Fig. 2:

Survival based on clinical IRC assessment by best response to romidepsin (n = 130). Progression-free survival (a) and overall survival (b). Patients with insufficient efficacy data to determine response due to early termination (NE; n = 29) were included as nonresponders. NE not evaluable

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us